Evaluation of Short-Term (1st and 3rd Month) Anthropometric Results in Obesity Patients Initiating Semaglutide Treatment: Experience of Two Tertiary Centers

Öz

Objective: This study aimed to evaluate the weight and Body Mass Index (BMI) changes at the 1st and 3rd months in obese patients with high treatment adherence who started semaglutide treatment at two tertiary hospitals in Diyarbakır, Türkiye Methods: This retrospective cohort study included 170 patients who started semaglutide treatment, regularly attended their 1st and 3rd-month follow-ups, and did not discontinue treatment. The patients' initial, 1st-month, and 3rd-month weight and BMI values were recorded. Statistical analysis was performed using the repeated measures ANOVA test. Results: The patients' initial mean weight was 104.97 ± 14.53 kg, and the mean BMI was 37.07 ± 4.38 kg/m². At the end of the 3rd month of treatment, the mean weight decreased to 96.04 ± 13.92 kg, and the mean BMI decreased to 33.92 ± 4.20 kg/m². A statistically significant difference was found between the baseline, 1st-month, and 3rd-month measurements for both weight and BMI values (p<0.001). Patients lost an average of 8.51% of their initial body weight after 3 months. Conclusion: Semaglutide treatment provides a high rate of clinically significant weight loss in the short term in obese patients with high treatment adherence.

Anahtar Kelimeler

• Obesity
• Semaglutide
• GLP-1 Receptor Agonists
• Body Mass Index

Semaglutide Başlanan Obezite Hastalarında Kısa Dönem (1. ve 3. Ay) Antropometrik Sonuçların Değerlendirilmesi: İki Üçüncü Basamak Merkez Deneyimi

Öz

Amaç: Bu çalışmanın amacı, Diyarbakır'daki iki üçüncü basamak hastanede semaglutid tedavisine başlanan ve tedaviye yüksek uyum gösteren obezite hastalarında 1. ve 3. aylardaki kilo ve Vücut Kitle İndeksi (VKİ) değişimlerini değerlendirmektir. Yöntemler: Bu retrospektif kohort çalışmaya, semaglutid tedavisine başlanan, 1. ve 3. ay kontrollerine düzenli gelen ve tedaviyi kesmeyen toplam 170 hasta dahil edildi. Hastaların başlangıç, 1. ay ve 3. ay kilo ve VKİ değerleri kaydedildi. İstatistiksel analiz Tekrarlayan Ölçümler ANOVA testi ile yapıldı. Bulgular: Hastaların başlangıç ortalama kilosu 104,97 ± 14,53 kg ve ortalama VKİ'si 37,07 ± 4,38 kg/m² olarak bulundu. Tedavinin 3. ayı sonunda ortalama kilo 96,04 ± 13,92 kg'a, ortalama VKİ ise 33,92 ± 4,20 kg/m²'ye düştü. Kilo ve VKİ değerlerinin başlangıç, 1. ay ve 3. ay ölçümleri arasında istatistiksel olarak anlamlı bir fark saptandı (p<0,001). Hastalar 3 ay sonunda başlangıç kilolarının ortalama %8,51'ini kaybetti. Sonuç: Semaglutid tedavisi, yüksek uyumlu obezite hastalarında kısa dönemde klinik açıdan anlamlı düzeyde kilo kaybı sağlamaktadır.

Anahtar Kelimeler

• Obezite
• Semaglutid
• GLP-1 Reseptör Agonistleri
• Vücut Kitle İndeksi.

Kaynakça

1. 1. Bray GA, Heisel WE, Afshin A, et al. The science of obesity management: an Endocrine Society scientific statement. Endocr Rev. 2018;39(2):79-132.
2. 2.Blundell J, Finlayson G, Axelsen M, et al. Effects ofonce-weekly semaglutide on appetite, energy intake,control of eating, food preference and body weightin subjects with obesity. Diabetes Obes Metab.2017;19(9):1242-51.
3. 3.Kapitza C, Dahl K, Jacobsen JB, Axelsen MB, Flint A.Effects of semaglutide on beta cell function andgastric emptying in subjects with type 2 diabetes.Diabetes Obes Metab. 2017;19(7):954-61.
4. 4.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight orObesity. N Engl J Med. 2021;384(11):989-1002.
5. 5.Jensen MD, Ryan DH, Apovian CM, et al. 2013AHA/ACC/TOS guideline for the management ofoverweight and obesity in adults: a report of theAmerican College of Cardiology/American HeartAssociation Task Force on Practice Guidelines andThe Obesity Society. Circulation. 2014;129(25 Suppl2): S102-38.
6. 6.Sorli C, Harashima SI, Tsoukas GM, et al. Efficacyand safety of once-weekly semaglutidemonotherapy versus placebo in patients with type 2diabetes (SUSTAIN 1): a double-blind, randomised,placebo-controlled, parallel-group, multinational,multicentre phase 3a trial. Lancet DiabetesEndocrinol. 2017;5(4):251-60.
7. 7.Kushner RF. Weight loss strategies for treatmentof obesity: lifestyle management and pharmacotherapy. Prog Cardiovasc Dis. 2018;61(2):246-52.
8. 8.Wing RR, Lang W, Wadden TA, et al. Benefits ofmodest weight loss in improving cardiovascular risk factors in overweight and obese individuals withtype 2 diabetes. Diabetes Care. 2011;34(7):1481-6.

9. 9.Nackers LM, Ross KM, Perri MG. The associationbetween rate of initial weight loss and long-termsuccess in obesity treatment: does slow and steadywin the race? Int J Behav Med. 2010;17(3):161-7.
10. 10. Moldovan A, Gagnon C, Hould FS, et al. Long-termweight loss and health status after bariatric surgery.Obes Surg. 2006;16(5):579-84.
11. 11.Secher A, Jelsing J, Baquero AF, et al. The arcuatenucleus mediates GLP-1 receptor agonistliraglutide-dependent weight loss. J Clin Invest.2014;124(10):4473-88.
12. 12.Van Can J, Sloth B, Jensen CB, et al. Effects of theonce-daily GLP-1 analog liraglutide on gastricemptying, glycemic parameters, appetite and energymetabolism in obese, non-diabetic adults. Int J Obes(Lond). 2014;38(6):784-93.
13. 13.Khera R, Murad MH, Chandar AK, et al.Association of Pharmacological Treatments forObesity With Weight Loss and Adverse Events: ASystematic Review and Meta-analysis. JAMA.2016;315(22):2424-34.
14. 14.Aroda VR. A review of GLP-1 receptor agonists:Evolution and advancement, through the lens ofrandomised controlled trials. Diabetes Obes Metab.2018;20 Suppl 1:22-33.
15. 15.Davies M, Færch L, Jeppesen OK, et al.Semaglutide 2·4 mg once a week in adults withoverweight or obesity, and type 2 diabetes (STEP 2):a randomised, double-blind, double-dummy,placebo-controlled, phase 3 trial. Lancet.2021;397(10278):971-84.
16. 16.Pratley R, Amod A, Hoff ST, et al. Oralsemaglutide versus subcutaneous liraglutide andplacebo in type 2 diabetes (PIONEER 4): arandomised, double-blind, phase 3a trial. Lancet.2019;394(10192):39-50.
17. 17.Rubino D, Abrahamsson N, Davies M, et al. Effectof Continued Weekly Subcutaneous Semaglutide vsPlacebo on Weight Loss Maintenance in Adults WithOverweight or Obesity: The STEP 4 RandomizedClinical Trial. JAMA. 2021;325(14):1414-25.
18. 18.Williams EP, Mesidor M, Winters K, Dubbert PM,Wyatt SB. Overweight and Obesity: Prevalence,Consequences, and Causes of a Growing PublicHealth Problem. Curr Obes Rep. 2015;4(3):363-70.
19. 19.Ekhart C, de Jong A, van Hunsel F. The Effect ofData Collection Methods on the SpontaneousReporting of Adverse Drug Reactions by HealthcareProfessionals: A Retrospective Analysis of PublicData. Drug Saf. 2021;44(5):569-78.